Dysport and Daxxify get compared because they occupy different corners of the neurotoxin market — one established and familiar, the other marketed around duration — and patients and injectors weigh them on the two axes that actually matter chairside: how the product spreads and how long it lasts. For an owner, the comparison is less about a clinical leaderboard and more about which selling point fits which patient, and how the cost-and-loyalty math works out.
This is general education for owners, not medical advice. Clinical decisions belong to trained injectors.